Highly Active Relapsing-Remitting Multiple Sclerosis with Neurofibromatosis Type 1: Radiological Aspects and Therapeutic Challenges – Case Report
Abstract Introduction: Multiple sclerosis (MS) is an autoimmune neurodegenerative disease which can rarely co-exist with neurofibromatosis 1 (NF1), a neurocutaneous inherited disorder that predisposes to oncogenesis. Patients who suffer from both conditions can be challenging cases for clinicians, a...
Gespeichert in:
| Veröffentlicht in: | Case reports in neurology 2024-01, Vol.16 (1), p.48-54 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 54 |
|---|---|
| container_issue | 1 |
| container_start_page | 48 |
| container_title | Case reports in neurology |
| container_volume | 16 |
| creator | Lemonaris, Marios Kleopa, Kleopas A. |
| description | Abstract
Introduction: Multiple sclerosis (MS) is an autoimmune neurodegenerative disease which can rarely co-exist with neurofibromatosis 1 (NF1), a neurocutaneous inherited disorder that predisposes to oncogenesis. Patients who suffer from both conditions can be challenging cases for clinicians, as clinical symptoms and radiological findings may overlap, while MS immune-modifying treatments could further increase the risk of oncogenesis. Case Presentation: In this study, we describe the case of a 27-year-old woman who presented with signs and symptoms of optic neuritis and was then diagnosed with both MS and NF1. As the patient continued to experience MS relapses despite initial interferon-beta treatment, she was subsequently switched to natalizumab and responded well. Conclusion: This case illustrates how MRI lesion differentiation with the co-existence of MS and NF1 can be difficult due to overlaps in lesion characteristics, while treatment decisions can be challenging mainly due to scarce data on the oncogenic risk of MS immunomodulary therapies. Therefore, clinicians need to balance out the risk of malignancy development with the risk of progressive neurological disability when treating such patients. |
| doi_str_mv | 10.1159/000536463 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_38405018</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_73a96ea2fc3d41629aad9d4b8f56db1f</doaj_id><sourcerecordid>3070509146</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-8db52e48c5ad6eefbfcd262cb3486258d10339a3c70cea81050fbbbd53ba5f233</originalsourceid><addsrcrecordid>eNptkUGP0zAQhS0EYpfCgTtCljhxKNhx4ibcqohlV1oWqRSJWzS2J6mLWwfbYdUb_2H_Ib-EdFsKB04ejZ6-98aPkOecveG8qN4yxgohcykekHMuZTaVJfv68J_5jDyJcc2YrAqZPyZnosxZwXh5Tu4ubbdyOzrXyf5AukAHfbTbbrrAjU1pnOjHwSXbO6SftcPgo4301qYVvcEh-Naq4DeQ7tfLXY-Uv6MLMNY731kNjs5jjzpFCltDlysM0OOQrKb1CpzDbYeR_vp5R2uIe_veh_SUPGrBRXx2fCfky8X7ZX05vf704aqeX0-1qFialkYVGealLsBIxFa12mQy00rkpcyK0nAmRAVCz5hGKPl4cauUMoVQULSZEBNydeAaD-umD3YDYdd4sM39woeugTBGddjMBFQSIWu1MDmXWQVgKpOrsi2kUbwdWa8OrD747wPG1Kz9ELZj_Eaw2Whd8bGfCXl9UOnxH2PA9uTKWbOvsjlVOWpfHomD2qA5Kf9099fyG4QOw0lQL24OiKY3-2Av_qs6uvwGKJaxbA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3070509146</pqid></control><display><type>article</type><title>Highly Active Relapsing-Remitting Multiple Sclerosis with Neurofibromatosis Type 1: Radiological Aspects and Therapeutic Challenges – Case Report</title><source>DOAJ Directory of Open Access Journals</source><source>Karger Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Lemonaris, Marios ; Kleopa, Kleopas A.</creator><creatorcontrib>Lemonaris, Marios ; Kleopa, Kleopas A.</creatorcontrib><description>Abstract
Introduction: Multiple sclerosis (MS) is an autoimmune neurodegenerative disease which can rarely co-exist with neurofibromatosis 1 (NF1), a neurocutaneous inherited disorder that predisposes to oncogenesis. Patients who suffer from both conditions can be challenging cases for clinicians, as clinical symptoms and radiological findings may overlap, while MS immune-modifying treatments could further increase the risk of oncogenesis. Case Presentation: In this study, we describe the case of a 27-year-old woman who presented with signs and symptoms of optic neuritis and was then diagnosed with both MS and NF1. As the patient continued to experience MS relapses despite initial interferon-beta treatment, she was subsequently switched to natalizumab and responded well. Conclusion: This case illustrates how MRI lesion differentiation with the co-existence of MS and NF1 can be difficult due to overlaps in lesion characteristics, while treatment decisions can be challenging mainly due to scarce data on the oncogenic risk of MS immunomodulary therapies. Therefore, clinicians need to balance out the risk of malignancy development with the risk of progressive neurological disability when treating such patients.</description><identifier>ISSN: 1662-680X</identifier><identifier>EISSN: 1662-680X</identifier><identifier>DOI: 10.1159/000536463</identifier><identifier>PMID: 38405018</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Antibodies ; case report ; Case reports ; Genetic disorders ; Glioma ; Lymphocytes ; Medical diagnosis ; Medical screening ; Monoclonal antibodies ; Multiple sclerosis ; natalizumab ; neurofibromatosis 1 ; Optic nerve ; Patients ; Proteins ; relapsing-remitting multiple sclerosis ; Single Case – General Neurology ; Spinal cord ; Visual impairment</subject><ispartof>Case reports in neurology, 2024-01, Vol.16 (1), p.48-54</ispartof><rights>2024 The Author(s). Published by S. Karger AG, Basel</rights><rights>2024 The Author(s). Published by S. Karger AG, Basel.</rights><rights>2024 The Author(s). Published by S. Karger AG, Basel. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at: https://uk.sagepub.com/en-gb/eur/reusing-open-access-and-sage-choice-content</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c390t-8db52e48c5ad6eefbfcd262cb3486258d10339a3c70cea81050fbbbd53ba5f233</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,2095,27614,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38405018$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lemonaris, Marios</creatorcontrib><creatorcontrib>Kleopa, Kleopas A.</creatorcontrib><title>Highly Active Relapsing-Remitting Multiple Sclerosis with Neurofibromatosis Type 1: Radiological Aspects and Therapeutic Challenges – Case Report</title><title>Case reports in neurology</title><addtitle>Case Rep Neurol</addtitle><description>Abstract
Introduction: Multiple sclerosis (MS) is an autoimmune neurodegenerative disease which can rarely co-exist with neurofibromatosis 1 (NF1), a neurocutaneous inherited disorder that predisposes to oncogenesis. Patients who suffer from both conditions can be challenging cases for clinicians, as clinical symptoms and radiological findings may overlap, while MS immune-modifying treatments could further increase the risk of oncogenesis. Case Presentation: In this study, we describe the case of a 27-year-old woman who presented with signs and symptoms of optic neuritis and was then diagnosed with both MS and NF1. As the patient continued to experience MS relapses despite initial interferon-beta treatment, she was subsequently switched to natalizumab and responded well. Conclusion: This case illustrates how MRI lesion differentiation with the co-existence of MS and NF1 can be difficult due to overlaps in lesion characteristics, while treatment decisions can be challenging mainly due to scarce data on the oncogenic risk of MS immunomodulary therapies. Therefore, clinicians need to balance out the risk of malignancy development with the risk of progressive neurological disability when treating such patients.</description><subject>Antibodies</subject><subject>case report</subject><subject>Case reports</subject><subject>Genetic disorders</subject><subject>Glioma</subject><subject>Lymphocytes</subject><subject>Medical diagnosis</subject><subject>Medical screening</subject><subject>Monoclonal antibodies</subject><subject>Multiple sclerosis</subject><subject>natalizumab</subject><subject>neurofibromatosis 1</subject><subject>Optic nerve</subject><subject>Patients</subject><subject>Proteins</subject><subject>relapsing-remitting multiple sclerosis</subject><subject>Single Case – General Neurology</subject><subject>Spinal cord</subject><subject>Visual impairment</subject><issn>1662-680X</issn><issn>1662-680X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>M--</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DOA</sourceid><recordid>eNptkUGP0zAQhS0EYpfCgTtCljhxKNhx4ibcqohlV1oWqRSJWzS2J6mLWwfbYdUb_2H_Ib-EdFsKB04ejZ6-98aPkOecveG8qN4yxgohcykekHMuZTaVJfv68J_5jDyJcc2YrAqZPyZnosxZwXh5Tu4ubbdyOzrXyf5AukAHfbTbbrrAjU1pnOjHwSXbO6SftcPgo4301qYVvcEh-Naq4DeQ7tfLXY-Uv6MLMNY731kNjs5jjzpFCltDlysM0OOQrKb1CpzDbYeR_vp5R2uIe_veh_SUPGrBRXx2fCfky8X7ZX05vf704aqeX0-1qFialkYVGealLsBIxFa12mQy00rkpcyK0nAmRAVCz5hGKPl4cauUMoVQULSZEBNydeAaD-umD3YDYdd4sM39woeugTBGddjMBFQSIWu1MDmXWQVgKpOrsi2kUbwdWa8OrD747wPG1Kz9ELZj_Eaw2Whd8bGfCXl9UOnxH2PA9uTKWbOvsjlVOWpfHomD2qA5Kf9099fyG4QOw0lQL24OiKY3-2Av_qs6uvwGKJaxbA</recordid><startdate>20240101</startdate><enddate>20240101</enddate><creator>Lemonaris, Marios</creator><creator>Kleopa, Kleopas A.</creator><general>S. Karger AG</general><general>Karger Publishers</general><scope>M--</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>DOA</scope></search><sort><creationdate>20240101</creationdate><title>Highly Active Relapsing-Remitting Multiple Sclerosis with Neurofibromatosis Type 1: Radiological Aspects and Therapeutic Challenges – Case Report</title><author>Lemonaris, Marios ; Kleopa, Kleopas A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-8db52e48c5ad6eefbfcd262cb3486258d10339a3c70cea81050fbbbd53ba5f233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antibodies</topic><topic>case report</topic><topic>Case reports</topic><topic>Genetic disorders</topic><topic>Glioma</topic><topic>Lymphocytes</topic><topic>Medical diagnosis</topic><topic>Medical screening</topic><topic>Monoclonal antibodies</topic><topic>Multiple sclerosis</topic><topic>natalizumab</topic><topic>neurofibromatosis 1</topic><topic>Optic nerve</topic><topic>Patients</topic><topic>Proteins</topic><topic>relapsing-remitting multiple sclerosis</topic><topic>Single Case – General Neurology</topic><topic>Spinal cord</topic><topic>Visual impairment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lemonaris, Marios</creatorcontrib><creatorcontrib>Kleopa, Kleopas A.</creatorcontrib><collection>Karger Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Case reports in neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lemonaris, Marios</au><au>Kleopa, Kleopas A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Highly Active Relapsing-Remitting Multiple Sclerosis with Neurofibromatosis Type 1: Radiological Aspects and Therapeutic Challenges – Case Report</atitle><jtitle>Case reports in neurology</jtitle><addtitle>Case Rep Neurol</addtitle><date>2024-01-01</date><risdate>2024</risdate><volume>16</volume><issue>1</issue><spage>48</spage><epage>54</epage><pages>48-54</pages><issn>1662-680X</issn><eissn>1662-680X</eissn><abstract>Abstract
Introduction: Multiple sclerosis (MS) is an autoimmune neurodegenerative disease which can rarely co-exist with neurofibromatosis 1 (NF1), a neurocutaneous inherited disorder that predisposes to oncogenesis. Patients who suffer from both conditions can be challenging cases for clinicians, as clinical symptoms and radiological findings may overlap, while MS immune-modifying treatments could further increase the risk of oncogenesis. Case Presentation: In this study, we describe the case of a 27-year-old woman who presented with signs and symptoms of optic neuritis and was then diagnosed with both MS and NF1. As the patient continued to experience MS relapses despite initial interferon-beta treatment, she was subsequently switched to natalizumab and responded well. Conclusion: This case illustrates how MRI lesion differentiation with the co-existence of MS and NF1 can be difficult due to overlaps in lesion characteristics, while treatment decisions can be challenging mainly due to scarce data on the oncogenic risk of MS immunomodulary therapies. Therefore, clinicians need to balance out the risk of malignancy development with the risk of progressive neurological disability when treating such patients.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>38405018</pmid><doi>10.1159/000536463</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1662-680X |
| ispartof | Case reports in neurology, 2024-01, Vol.16 (1), p.48-54 |
| issn | 1662-680X 1662-680X |
| language | eng |
| recordid | cdi_pubmed_primary_38405018 |
| source | DOAJ Directory of Open Access Journals; Karger Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Antibodies case report Case reports Genetic disorders Glioma Lymphocytes Medical diagnosis Medical screening Monoclonal antibodies Multiple sclerosis natalizumab neurofibromatosis 1 Optic nerve Patients Proteins relapsing-remitting multiple sclerosis Single Case – General Neurology Spinal cord Visual impairment |
| title | Highly Active Relapsing-Remitting Multiple Sclerosis with Neurofibromatosis Type 1: Radiological Aspects and Therapeutic Challenges – Case Report |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T22%3A43%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Highly%20Active%20Relapsing-Remitting%20Multiple%20Sclerosis%20with%20Neurofibromatosis%20Type%201:%20Radiological%20Aspects%20and%20Therapeutic%20Challenges%20%E2%80%93%20Case%20Report&rft.jtitle=Case%20reports%20in%20neurology&rft.au=Lemonaris,%20Marios&rft.date=2024-01-01&rft.volume=16&rft.issue=1&rft.spage=48&rft.epage=54&rft.pages=48-54&rft.issn=1662-680X&rft.eissn=1662-680X&rft_id=info:doi/10.1159/000536463&rft_dat=%3Cproquest_pubme%3E3070509146%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3070509146&rft_id=info:pmid/38405018&rft_doaj_id=oai_doaj_org_article_73a96ea2fc3d41629aad9d4b8f56db1f&rfr_iscdi=true |